Precision medicine

Notable Labs to Present Analysis of Hematologic Oncology Drug Sensitivity Data

Branches of biology, Life sciences, Biology, Molecular biology, Drug development, Drug discovery, Pharmaceutical industry, RNA-Seq, Precision medicine
Wednesday, January 27, 2021 - 12:00pm

"This webinar will highlight the integration of three technologies: a flow-cytometry drug sensitivity screen, DNA-Seq, and RNA-Seq," said CEO Laurie Heilmann.

Key Points: 
  • "This webinar will highlight the integration of three technologies: a flow-cytometry drug sensitivity screen, DNA-Seq, and RNA-Seq," said CEO Laurie Heilmann.
  • "By augmenting a stand-alone drug sensitivity screen with multi-omic data, Notable Labs is amassing a continually-growing dataset that ultimately will provide utility for drug development and patient care in AML and other hematologic oncology indications."
  • The webinar will cover how this dataset, containing samples with matched drug sensitivity, gene expression, and variant data, enables researchers to look at the relationships between different data types.
  • Notable's functional precision medicine platform will advance drug development and enable pharmaceutical companies to get new therapies topatientsfaster.

OncoHost Secures $8 Million Series B Funding Round to Advance its AI-Powered Precision Oncology Platform

OurCrowd, Precision medicine, Oncology
Tuesday, January 19, 2021 - 1:00pm

BINYAMINA, Israel, Jan. 19, 2021 /PRNewswire/ -- OncoHost , global leader in host response profiling for improved personalized cancer therapy, today announced the completion of a $8 million Series B funding round.

Key Points: 
  • BINYAMINA, Israel, Jan. 19, 2021 /PRNewswire/ -- OncoHost , global leader in host response profiling for improved personalized cancer therapy, today announced the completion of a $8 million Series B funding round.
  • The funding round was led by OurCrowd ,an investment platform built for accredited investors and institutions to invest in start-ups, early-stage companies and venture funds.
  • OncoHost is demonstrating that smart software can take an already promising technology such as immunotherapy and make it so much smarter."
  • OncoHost is a clinical stage precision oncology start-up, combininglife-science research and advanced machine learning technology to develop personalized strategies for cancer patients.

Paige Announces Series C Funding Round of $100 Million to Accelerate Transformation of Digital Pathology

Biotechnology, Health, Medical devices, Given names, Branches of biology, Biology, Systems biology, Pathology, Paige, Digital pathology, Precision medicine, Johnson & Johnson
Thursday, January 14, 2021 - 12:00pm

Paige , a global leader in AI-based digital diagnostics, today announced a Series C funding round of $100 million to accelerate the Companys efforts to transform digital pathology by unlocking insights from each patients sample so pathologists, care teams and researchers can make decisions more confidently and efficiently to optimize outcomes.

Key Points: 
  • Paige , a global leader in AI-based digital diagnostics, today announced a Series C funding round of $100 million to accelerate the Companys efforts to transform digital pathology by unlocking insights from each patients sample so pathologists, care teams and researchers can make decisions more confidently and efficiently to optimize outcomes.
  • The Series C financing was led by Casdin Capital and Johnson & Johnson Innovation JJDC, Inc. (JJDC), the strategic venture capital arm of Johnson & Johnson.
  • Paige is building a transformational portfolio of computational pathology products to serve clinical needs and drive precision medicine, said Leo Grady, Ph.D., Chief Executive Officer, Paige.
  • This investment reaffirms the vast potential of the Paige platform for clinical and biopharmaceutical drug development applications.

Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology

Branches of biology, Academic disciplines, Biology, Exact Sciences, Exact Sciences, Precision medicine, Medical diagnosis, Residual
Wednesday, January 13, 2021 - 7:45pm

This compelling and technically distinct approach will help expand Exact Sciences' leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.

Key Points: 
  • This compelling and technically distinct approach will help expand Exact Sciences' leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.
  • "The scale and reach Exact Sciences brings to the market means greater access and new hope for patients faced with a cancer diagnosis."
  • XMS Capital is serving as financial advisor to Exact Sciences, and K&L Gates is serving as legal advisor.
  • For more information, please visit the company's website at www.ExactSciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Progenity Provides Financial Guidance for Full-year 2021

Evidence-based medicine, Precision medicine, Systems biology, Medical genetics
Wednesday, January 13, 2021 - 9:05pm

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine.

Key Points: 
  • Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine.
  • Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages.
  • For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com .
  • These statements reflect our plans, estimates, and expectations, as of the date of this press release, including revenue, expense and volume guidance for the fiscal year 2021.

Anticancer Bioscience Presenting at Biotech Showcase(TM) Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time

Genetics, Synthetic lethality, Precision medicine
Wednesday, January 13, 2021 - 2:34pm

Chengdu, China--(Newsfile Corp. - January 13, 2021) - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today announced that it is participating in Biotech Showcase Digital 2021, for the first time, providing an on-demand company presentation.

Key Points: 
  • Chengdu, China--(Newsfile Corp. - January 13, 2021) - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today announced that it is participating in Biotech Showcase Digital 2021, for the first time, providing an on-demand company presentation.
  • Anticancer Bioscience is participating in Biotech Showcase Digital 2021.
  • The Company will showcase its pioneering approach to precision oncology, and how it is applying its synthetic lethality expertise for better cancer therapies.
  • Pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China.

Strata Oncology Announces Personalized Recurrence Monitoring Trial

Medicine, Clinical medicine, Oncology, Precision medicine, Biopsy, Branches of biology, Medical tests, Molecular diagnostics
Wednesday, January 13, 2021 - 12:30pm

"The Sentinel Trial will support the validation of our personalized recurrence monitoring assay for patients with solid tumors in a diverse population," said Dan Rhodes , PhD, co-founder and Chief Executive Officer, Strata Oncology.

Key Points: 
  • "The Sentinel Trial will support the validation of our personalized recurrence monitoring assay for patients with solid tumors in a diverse population," said Dan Rhodes , PhD, co-founder and Chief Executive Officer, Strata Oncology.
  • The Sentinel Trial will pair simultaneous DNA and RNA tissue-based molecular profiling with liquid biopsy-based recurrence monitoring.
  • Strata Oncology recently made StrataNGSTM broadly available in the U.S. based on its experience processing more than 40,000 tissue specimens from patients with advanced cancer through the Strata Trial.
  • Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer.

Genetron Health to Present at BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021

Research, FDA, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Evidence-based medicine, Precision medicine, Systems biology, Draft:Genetron Health
Wednesday, January 13, 2021 - 11:30am

Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021.

Key Points: 
  • Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021.
  • Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
  • Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
  • Further information regarding these and other risks, uncertainties or factors is included in the Companys filings with the SEC.

CES 2021 Taiwanese biotech startup mProbe CADx develops AI health analysis platform

Evidence-based medicine, Precision medicine, Systems biology, Taipei, Biotechnology
Tuesday, January 12, 2021 - 6:49pm

TAIPEI, Jan. 12, 2021 /PRNewswire/ -- mProbe Taiwan is a subsidiary biotechnology company of mProbe Inc, committed to promoting human health and wellness by transforming the field of precision health and precision medicine.

Key Points: 
  • TAIPEI, Jan. 12, 2021 /PRNewswire/ -- mProbe Taiwan is a subsidiary biotechnology company of mProbe Inc, committed to promoting human health and wellness by transforming the field of precision health and precision medicine.
  • mProbe CADx can quantify the health status, assess the risk of disease, and give personalized intervention suggestions for health promotion," said mProbe Vice President KuoYuan Hwa.
  • Personalized active health management - Combining biochemical testing, multi-omics testing and artificial intelligence analysis, using precise health checkup as an approach to monitor the risks and trajectoryof various diseases.
  • The innovative platform developed by mProbeTW has been selected by Taiwan Tech Arena (TTA) as one of the 100 featured Taiwanese startups to showcase at CES 2021.

Myriad Genetics Forms Strategic Partnership with Illumina in Oncology

Branches of biology, Biology, Microarrays, Biotechnology companies, DNA sequencing, Medical genetics, Illumina, Inc., Myriad Genetics, Precision medicine, Lumi
Monday, January 11, 2021 - 7:05pm

The agreement between Myriad and Illumina combines companion diagnostics and next-generation sequencing to advance comprehensive genomic profiling of tumor samples and drive improved outcomes in oncology, said Paul J. Diaz, president and CEO, Myriad Genetics.

Key Points: 
  • The agreement between Myriad and Illumina combines companion diagnostics and next-generation sequencing to advance comprehensive genomic profiling of tumor samples and drive improved outcomes in oncology, said Paul J. Diaz, president and CEO, Myriad Genetics.
  • This collaboration reflects our increasing focus on partnering with high-caliber healthcare leaders like Illumina to bring innovative solutions to the oncology market.
  • The strategic partnership with Myriad and Illumina consists of a time-limited exclusive agreement for Illumina to provide a kit-based version of the myChoice CDx test for international markets.
  • Illumina is committed to offering innovative diagnostic tools that power precision oncology, said Dr. Phil Febbo, M.D., Chief Medical Officer of Illumina.